Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

ABSTRACT Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A1c (A1C) and weight in clinical trials. The objective of this study was to evaluate the effects of ≥ 3 years exenatide therapy on glycemic control, body weight, cardiometabolic...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Current medical research and opinion 2008-01, Vol.24 (1), p.275-286
Hauptverfasser:	Klonoff, David C., Buse, John B., Nielsen, Loretta L., Guan, Xuesong, Bowlus, Christopher L., Holcombe, John H., Wintle, Matthew E., Maggs, David G.
Format:	Artikel
Sprache:	eng
Schlagworte:	ALT AST Exenatide Exendin-4 HDL-C Incretin mimetic LDL-C NAFLD Triglycerides Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!